<DOC>
	<DOCNO>NCT00288431</DOCNO>
	<brief_summary>This study design determine safety , tolerability maximum tolerate dose Oral AP23573 combination Doxorubicin</brief_summary>
	<brief_title>Safety , Tolerability Maximum Tolerated Dose Oral AP23573 Combination With Doxorubicin ( 8669-015 )</brief_title>
	<detailed_description>The primary objective determine maximum tolerate dose ( MTD ) AP23573 combination doxorubicin , characterize safety profile AP23573 combination doxorubicin , examine pharmacokinetics AP23573 doxorubicin give combination patient advanced malignancy .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age ≥ 18 year histological/cytological diagnosis advance tumor , preferentially breast , sarcoma , ovarian , endometrial tumor type treatment anthracycline therapy indicate Prior cumulative doxorubicin exposure le 400 mg/m2 An ECOG performance status 0 1 Adequate cardiovascular function Measurable disease accord modify RECIST criterion Adequate hematological , renal hepatic function Able understand give voluntary write informed consent Women pregnant lactate Presence active brain metastasis . Patients treat brain metastasis eligible stable dose corticosteroid without change brain disease status least 4 week follow related therapy ( e.g. , whole brain radiation , surgery ) Prior treatment CCI779 , rapamycin , mTOR inhibitor Prior anticancer treatment ( chemotherapy , radiotherapy , hormonal , immunotherapy , biological response modifier , signal transduction inhibitor , etc ) within 4 week prior first dose AP23573 ; interval ≥ 2 week signal transduction inhibitor halflife know &lt; 24 hour , ≥ 6 week nitrosourea mitomycin . Exception : Concurrent treatment LHRH agonists allow patient prostate cancer . Ongoing toxicity associate prior anticancer therapy alopecia ≤ Grade 1 peripheral neuropathy NCI toxicity criterion Another primary malignancy within past three year ( except nonmelanoma skin cancer cervical carcinoma situ ) Known suspect hypersensitivity excipient contain study drug Known Grade 3 4 hypersensitivity macrolide antibiotic ( e.g. , clarithromycin , erythromycin , azithromycin ) Significant uncontrolled cardiovascular disease Any active infection require prescribe intervention Any concurrent illness , opinion investigator , would either compromise patient 's safety interfere evaluation safety study drug Any preexisting malabsorption syndrome , irritable bowel syndrome clinical situation could affect oral absorption Concurrent treatment immunosuppressive agent prescribed corticosteroid stable dos ≥ 2 week prior first plan dose study drug Concurrent treatment medication induce inhibit cytochrome P450 ( CYP3A ) Inadequate recovery prior surgical procedure undergone major surgical procedure within 2 week prior first dose AP23573</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>cancer</keyword>
	<keyword>sarcoma</keyword>
</DOC>